Form 8-K - Current report:
SEC Accession No. 0001628280-24-048910
Filing Date
2024-11-22
Accepted
2024-11-21 21:43:46
Documents
20
Period of Report
2024-11-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K intensity-20241121.htm   iXBRL 8-K 39889
2 EX-1.1 exhibit11-8xk.htm EX-1.1 67343
3 EX-4.1 exhibit41-8xk.htm EX-4.1 135401
4 EX-5.1 exhibit51-8xk.htm EX-5.1 10861
5 EX-10.1 exhibit101-8xk.htm EX-10.1 275206
6 EX-99.1 exhibit991-8xk.htm EX-99.1 15676
10 mintzlogo.jpg GRAPHIC 10029
11 mintzlogo1.jpg GRAPHIC 5008
  Complete submission text file 0001628280-24-048910.txt   810352

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT intensity-20241121.xsd EX-101.SCH 1827
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT intensity-20241121_lab.xml EX-101.LAB 23449
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT intensity-20241121_pre.xml EX-101.PRE 13606
22 EXTRACTED XBRL INSTANCE DOCUMENT intensity-20241121_htm.xml XML 2935
Mailing Address 1 ENTERPRISE DRIVE, SUITE 430 SHELTON CT 06484
Business Address 1 ENTERPRISE DRIVE, SUITE 430 SHELTON CT 06484 203-221-7381
INTENSITY THERAPEUTICS, INC. (Filer) CIK: 0001567264 (see all company filings)

EIN.: 461488089 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41109 | Film No.: 241486210
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)